SYK Stryker Corporation
Excellent compounder with a robotic moat, but at $310 the market already prices in near-perfect execution.
The story
Stryker is a diversified medtech leader in orthopaedics (with Mako robotics as a growing installed-base moat), MedSurg and neurotechnology. It has compounded revenue at about 11% a year through high-single-digit organic growth plus steady tuck-in acquisitions such as Inari. It is a mature but still growing franchise. Hospital relationships, surgeon training and robotic lock-in support durable pricing and share, and operating leverage keeps lifting margins toward the mid-20s.
Growth, terminal growth, beta and failure risk stay the same; the TTM margin rose to 21.7%, so the target moves only slightly, from 24% to 25%. Sales-to-capital moves from 0.70 to 0.95 because the historical 0.69 is weighed down by acquisition goodwill, while organic growth needs little capital (capex of 0.87B runs below D&A of 1.21B). The horizon moves from 7 to 10 years because the Mako-driven moat looks more durable than I assumed, and my prior value sat more than 100% below a heavily covered price, which told me those two drivers were too harsh.
Value drivers
| Revenue growth (Y1) | 9.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 25.0% |
| Years to target margin | 5 |
| Sales-to-capital | 0.95 |
| Beta | 0.90 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.7% |
| Terminal WACC | 9.1% |
Valuation bridge
| PV of explicit FCFF | 27.30B |
| PV of terminal value | 47.05B |
| Equity value | 61.88B |
| ÷ shares → per share | $162.54 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 28.67B | 9.0% | 22.4% | 4.61B | 2.49B | 2.12B | 1.95B |
| 2 | 31.07B | 8.4% | 23.0% | 5.15B | 2.53B | 2.62B | 2.22B |
| 3 | 33.49B | 7.8% | 23.7% | 5.71B | 2.54B | 3.16B | 2.46B |
| 4 | 35.89B | 7.2% | 24.3% | 6.28B | 2.53B | 3.76B | 2.69B |
| 5 | 38.24B | 6.6% | 25.0% | 6.87B | 2.48B | 4.40B | 2.90B |
| 6 | 40.51B | 5.9% | 25.0% | 7.28B | 2.39B | 4.89B | 2.97B |
| 7 | 42.68B | 5.3% | 25.0% | 7.67B | 2.27B | 5.40B | 3.01B |
| 8 | 44.69B | 4.7% | 25.0% | 8.03B | 2.12B | 5.91B | 3.04B |
| 9 | 46.53B | 4.1% | 25.0% | 8.36B | 1.93B | 6.43B | 3.04B |
| 10 | 48.16B | 3.5% | 25.0% | 8.66B | 1.71B | 6.94B | 3.02B |
Key risks
- Acquisition-led growth destroys value if deal premiums keep inflating invested capital
- Hospital capital budget pressure or reimbursement cuts slow Mako and capital equipment sales
- Tariffs, supply-chain and pricing pressure stall margin expansion below 25%
Catalysts
- Mako expansion into spine and shoulder lifting installed base and procedure share
- Sustained 9%+ organic growth with adjusted operating margin expansion toward 26%